Delivery Order SPE2DB24D1205-SPE2DB25FCXWG
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 17, 2025, for the supply of Ibsrela 50 mg tablets (60-count units) with a ceiling value of $11,718.53. This firm fixed-price delivery order, which is due for completion by June 18, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The award was made through competitive...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Ibsrela 50 mg tablets (60 count) under a firm fixed-price contract valued at $4,847.75. This non-set-aside award is a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion vehicle that runs through December 2026 and supports pharmaceutical procurement for military and veteran...
- The Defense Logistics Agency awarded a delivery order valued at $7,346.49 to AmerisourceBergen Drug Corp for the supply of Ibsrela 50 mg tablets (60-count units) on September 11, 2025, with an ultimate completion date of September 12, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed price pricing and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $6,909.82 to AmerisourceBergen Drug Corp for Ibsrela 50 mg tablets (60-count units) on September 3, 2025, with completion expected by September 4, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania location. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Ibsrela 50 mg tablets (60 count) under a firm fixed-price contract valued at $14,991.13. This non-set-aside delivery order was competitively awarded and is set to complete by August 6, 2025. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $14,453.80 to AmerisourceBergen Drug Corp for the supply of Ibsrela 50 mg tablets (60-count units) on September 8, 2025, with completion targeted for September 9, 2025. This competitive, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Ibsrela 50 mg tablets (60-count units) under a firm fixed-price contract valued at $21,030.84, with completion expected by August 21, 2025. This competitively awarded, non-set-aside delivery order represents a routine pharmaceutical procurement supporting federal medical supply needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a...
- This delivery order, valued at $21,312.70, was awarded to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ibsrela 50 mg tablets in 60-count units to support federal medical procurement needs. The contract is non-competitive and utilizes firm fixed pricing with an ultimate completion date of September 10, 2025. The Defense Logistics Agency, which serves as the funding federal agency, awarded this order to supply pharmaceutical products to support military and veteran...
- The Defense Logistics Agency awarded a delivery order valued at $3,047.31 to AmerisourceBergen Drug Corp for 60 tablets of Ibsrela 50 mg on June 27, 2025. This competitive award, issued without set-aside provisions, is structured as a firm fixed price delivery order with an ultimate completion date of June 30, 2025. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen Drug Corp maintains its corporate office. This delivery order...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Ibsrela 50 mg tablets (60-count units) under a firm fixed-price contract valued at $3,784.00, with completion targeted for September 18, 2025. This is a competitively awarded, non-set-aside delivery order issued by the federal government's medical procurement division. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCXWGDelivery Order
The Defense Logistics Agency awarded a $3,431.04 firm fixed-price delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Ibsrela 50 mg tablets (60-count units). This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. Performance will be executed from the contractor's Conshohocken, Pennsylvania location, with an ultimate completion date of June 20, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor within the federal medical supply chain supporting military and veteran healthcare systems. The company holds multiple competitively awarded contracts with the Defense Logistics Agency, reflecting its capability to fulfill comprehensive pharmaceutical procurement requirements across diverse therapeutic domains. This delivery order for Ibsrela, a gastrointestinal medication, exemplifies the company's role in supplying specialized pharmaceutical products to support Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 6/18/25 |